Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Victoria Mateos

Showing results (121-130 of 211) with videos related to

Pageof 22
Sort By:
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
British Journal of Haematology|May 4, 2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaJacob P Laubach, Javid J Moslehi, Sanjeev A Francis, et al.
Pageof 22

Showing results (121-130 of 211) with videos related to

Sort By:
Pageof 22
The Lancet. Oncology|April 12, 2025
Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trialMaria-Victoria Mateos, Jesus San-Miguel, Michele Cavo, et al.
Lancet (London, England)|December 15, 2018
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trialMeletios A Dimopoulos, Francesca Gay, Fredrik Schjesvold, et al.
Current Medical Research and Opinion|July 11, 2022
Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myelomaLuciano J Costa, Parameswaran Hari, Jesus G Berdeja, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Blood Cancer Journal|December 3, 2021
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentageCarlos Fernández de Larrea, Robert Kyle, Laura Rosiñol, et al.
Haematologica|March 31, 2022
Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myelomaSaad Z Usmani, Hareth Nahi, Wojciech Legiec, et al.
Bone Marrow Transplantation|August 5, 2023
Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMTRémi Tilmont, Ibrahim Yakoub-Agha, Diderik-Jan Eikema, et al.
BMC Cancer|June 3, 2021
Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trialStefan Knop, Maria-Victoria Mateos, Meletios A Dimopoulos, et al.
Blood|January 25, 2012
IMWG consensus on maintenance therapy in multiple myelomaHeinz Ludwig, Brian G M Durie, Philip McCarthy, et al.
British Journal of Haematology|May 4, 2017
A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myelomaJacob P Laubach, Javid J Moslehi, Sanjeev A Francis, et al.
Pageof 22